These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 38580165)

  • 1. Vesicular monoamine transporter-2 inhibitor JPC-141 prevents methamphetamine-induced dopamine toxicity and blocks methamphetamine self-administration in rats.
    Chandler CM; Nickell JR; George Wilson A; Culver JP; Crooks PA; Bardo MT; Dwoskin LP
    Biochem Pharmacol; 2024 Oct; 228():116189. PubMed ID: 38580165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GZ-11608, a Vesicular Monoamine Transporter-2 Inhibitor, Decreases the Neurochemical and Behavioral Effects of Methamphetamine.
    Lee NR; Zheng G; Leggas M; Janganati V; Nickell JR; Crooks PA; Bardo MT; Dwoskin LP
    J Pharmacol Exp Ther; 2019 Nov; 371(2):526-543. PubMed ID: 31413138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New Scaffold for Lead Compounds to Treat Methamphetamine Use Disorders.
    Lee NR; Zheng G; Crooks PA; Bardo MT; Dwoskin LP
    AAPS J; 2018 Feb; 20(2):29. PubMed ID: 29427069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lobelane inhibits methamphetamine-evoked dopamine release via inhibition of the vesicular monoamine transporter-2.
    Nickell JR; Krishnamurthy S; Norrholm S; Deaciuc G; Siripurapu KB; Zheng G; Crooks PA; Dwoskin LP
    J Pharmacol Exp Ther; 2010 Feb; 332(2):612-21. PubMed ID: 19855096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. meso-Transdiene analogs inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine release.
    Horton DB; Siripurapu KB; Norrholm SD; Culver JP; Hojahmat M; Beckmann JS; Harrod SB; Deaciuc AG; Bardo MT; Crooks PA; Dwoskin LP
    J Pharmacol Exp Ther; 2011 Mar; 336(3):940-51. PubMed ID: 21177475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The novel pyrrolidine nor-lobelane analog UKCP-110 [cis-2,5-di-(2-phenethyl)-pyrrolidine hydrochloride] inhibits VMAT2 function, methamphetamine-evoked dopamine release, and methamphetamine self-administration in rats.
    Beckmann JS; Siripurapu KB; Nickell JR; Horton DB; Denehy ED; Vartak A; Crooks PA; Dwoskin LP; Bardo MT
    J Pharmacol Exp Ther; 2010 Dec; 335(3):841-51. PubMed ID: 20805303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel N-1,2-dihydroxypropyl analogs of lobelane inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine release.
    Horton DB; Siripurapu KB; Zheng G; Crooks PA; Dwoskin LP
    J Pharmacol Exp Ther; 2011 Oct; 339(1):286-97. PubMed ID: 21778282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral administration of GZ-793A, a VMAT2 inhibitor, decreases methamphetamine self-administration in rats.
    Wilmouth CE; Zheng G; Crooks PA; Dwoskin LP; Bardo MT
    Pharmacol Biochem Behav; 2013 Nov; 112():29-33. PubMed ID: 24075974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The vesicular monoamine transporter-2: an important pharmacological target for the discovery of novel therapeutics to treat methamphetamine abuse.
    Nickell JR; Siripurapu KB; Vartak A; Crooks PA; Dwoskin LP
    Adv Pharmacol; 2014; 69():71-106. PubMed ID: 24484975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GZ-793A, a lobelane analog, interacts with the vesicular monoamine transporter-2 to inhibit the effect of methamphetamine.
    Horton DB; Nickell JR; Zheng G; Crooks PA; Dwoskin LP
    J Neurochem; 2013 Oct; 127(2):177-86. PubMed ID: 23875622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GZ-793A inhibits the neurochemical effects of methamphetamine via a selective interaction with the vesicular monoamine transporter-2.
    Nickell JR; Siripurapu KB; Horton DB; Zheng G; Crooks PA; Dwoskin LP
    Eur J Pharmacol; 2017 Jan; 795():143-149. PubMed ID: 27986625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of VMAT2 inhibitors lobeline and GZ-793A on methamphetamine-induced changes in dopamine release, metabolism and synthesis in vivo.
    Meyer AC; Neugebauer NM; Zheng G; Crooks PA; Dwoskin LP; Bardo MT
    J Neurochem; 2013 Oct; 127(2):187-98. PubMed ID: 23875705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of a novel VMAT2 inhibitor, GZ-793A, on methamphetamine reward in rats.
    Beckmann JS; Denehy ED; Zheng G; Crooks PA; Dwoskin LP; Bardo MT
    Psychopharmacology (Berl); 2012 Mar; 220(2):395-403. PubMed ID: 21938414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tetrabenazine inhibition of monoamine uptake and methamphetamine behavioral effects: locomotor activity, drug discrimination and self-administration.
    Meyer AC; Horton DB; Neugebauer NM; Wooters TE; Nickell JR; Dwoskin LP; Bardo MT
    Neuropharmacology; 2011 Sep; 61(4):849-56. PubMed ID: 21669212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phenyl ring-substituted lobelane analogs: inhibition of [³H]dopamine uptake at the vesicular monoamine transporter-2.
    Nickell JR; Zheng G; Deaciuc AG; Crooks PA; Dwoskin LP
    J Pharmacol Exp Ther; 2011 Mar; 336(3):724-33. PubMed ID: 20876747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Environmental enrichment reduces methamphetamine cue-induced reinstatement but does not alter methamphetamine reward or VMAT2 function.
    Hofford RS; Darna M; Wilmouth CE; Dwoskin LP; Bardo MT
    Behav Brain Res; 2014 Aug; 270():151-8. PubMed ID: 24821405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lobeline attenuates methamphetamine-induced changes in vesicular monoamine transporter 2 immunoreactivity and monoamine depletions in the striatum.
    Eyerman DJ; Yamamoto BK
    J Pharmacol Exp Ther; 2005 Jan; 312(1):160-9. PubMed ID: 15331654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prior methamphetamine self-administration attenuates the dopaminergic deficits caused by a subsequent methamphetamine exposure.
    McFadden LM; Vieira-Brock PL; Hanson GR; Fleckenstein AE
    Neuropharmacology; 2015 Jun; 93():146-54. PubMed ID: 25645392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lobeline analogs with enhanced affinity and selectivity for plasmalemma and vesicular monoamine transporters.
    Miller DK; Crooks PA; Zheng G; Grinevich VP; Norrholm SD; Dwoskin LP
    J Pharmacol Exp Ther; 2004 Sep; 310(3):1035-45. PubMed ID: 15121762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased Vesicular Monoamine Transporter 2 (VMAT2; Slc18a2) Protects against Methamphetamine Toxicity.
    Lohr KM; Stout KA; Dunn AR; Wang M; Salahpour A; Guillot TS; Miller GW
    ACS Chem Neurosci; 2015 May; 6(5):790-9. PubMed ID: 25746685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.